article thumbnail

Pfizer COVID vaccine under EMA review for younger teens

The Pharma Data

The European Medicines Agency (EMA) is evaluating an application submitted by Pfizer and BioNTech for use of their COVID-19 vaccine in children aged 12 to 15 years. . The vaccine has been authorized by the EU for use in people 16 years and up since December 2020. . Pfizer also shared antibody responses from the younger age group.

Vaccine 52
article thumbnail

AstraZeneca’s COVID-19 Vaccine Boasts Strong Results with Up to 90% Efficacy

The Pharma Data

As the Pfizer and BioNTech COVID-19 vaccine goes to regulators and the Moderna vaccine approaches the end of its Phase III trials, AstraZeneca and the University of Oxford announced high-level results from an interim analysis of their COVID-19 vaccine, AZD1222. The combined analysis showed average efficacy of 70%.

Vaccine 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

China’s ‘insect’ vaccine for COVID-19 approved for human testing

The Pharma Data

China is set to move ahead with human testing of a potential coronavirus vaccine that has been created using insect cells. It is hoped that using insect cells to grow proteins for the vaccine could speed up large-scale production. These were primarily border officials and health workers. Conor Kavanagh. Source link.

Vaccine 40
article thumbnail

Keeping tabs on Covid-19: FDA approves Veklury as first treatment for Covid-19 and Takeda and Moderna bring 50 million vaccines to Japan

The Pharma Data

Takeda and Moderna join forces to expand Covid-19 vaccine supply in Japan. A three-way agreement between Takeda , Moderna and the Government of Japan’s Ministry of Health Labour and Welfare (MHLW) plans to bring mRNA-1273, Moderna’s Covid-19 vaccine candidate, to Japan. Source link.

article thumbnail

Novavax COVID-19 vaccine demonstrates 90% overall efficacy and 100% protection against moderate and severe disease in PREVENT-19 Phase 3 trial

The Pharma Data

Nasdaq: NVAX), today announced that NVX-CoV2373, its recombinant nanoparticle protein-based COVID-19 vaccine, demonstrated 100% protection against moderate and severe disease, 90.4% “Today, Novavax is one step closer to addressing the critical and persistent global public health need for additional COVID-19 vaccines. Glenn, M.D.,

Vaccine 40
article thumbnail

Tonix Pharmaceuticals Enrolls First Participant in the PRECISION Study, an Observational Study to Facilitate Development of Precision Medicine Techniques for COVID-19 Vaccines and Therapeutics

The Pharma Data

Study May Lead to Biomarkers for Tailoring COVID-19 Vaccines and Therapeutics. Such aptamers have the potential to identify biomarkers for protective CoV-2 immunity and may lead to accelerated precision medicine-driven vaccines designed to protect against COVID-19. CHATHAM, N.J., About TNX-1800. 1 Noyce RS, et al.

Vaccine 40
article thumbnail

Package | Prasara Yoga

The Pharma Data

Product Name: Package | Prasara Yoga. Click here to get Package | Prasara Yoga at discounted price while it’s still available… All orders are protected by SSL encryption – the highest industry standard for online security from trusted vendors. You will NOT receive a physical package shipped to you in the mail.